SeaSpine (SPNE) PT Set at $15.00 by HC Wainwright
Several other research firms have also commented on SPNE. Zacks Investment Research lowered shares of SeaSpine from a buy rating to a hold rating in a report on Friday, January 5th. Ladenburg Thalmann Financial Services began coverage on shares of SeaSpine in a research report on Thursday, December 14th. They set a buy rating and a $20.00 price target for the company. Finally, BTIG Research reissued a buy rating on shares of SeaSpine in a research report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. SeaSpine presently has an average rating of Buy and a consensus target price of $17.25.
SeaSpine (NASDAQ SPNE) traded down $0.27 during mid-day trading on Friday, hitting $9.91. 83,367 shares of the company traded hands, compared to its average volume of 39,486. SeaSpine has a 52 week low of $6.31 and a 52 week high of $13.46. The company has a market cap of $136.71, a price-to-earnings ratio of -3.80 and a beta of 0.36.
Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in SeaSpine by 10.6% during the 2nd quarter. Vanguard Group Inc. now owns 334,832 shares of the medical equipment provider’s stock valued at $3,857,000 after buying an additional 32,191 shares during the period. FNY Partners Fund LP boosted its position in SeaSpine by 44.2% during the 3rd quarter. FNY Partners Fund LP now owns 59,102 shares of the medical equipment provider’s stock valued at $663,000 after buying an additional 18,102 shares during the period. OxFORD Asset Management LLP boosted its position in SeaSpine by 86.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 46,527 shares of the medical equipment provider’s stock valued at $524,000 after buying an additional 21,520 shares during the period. Royce & Associates LP purchased a new stake in SeaSpine during the 3rd quarter valued at $481,000. Finally, Hodges Capital Management Inc. boosted its position in SeaSpine by 50.0% during the 3rd quarter. Hodges Capital Management Inc. now owns 180,000 shares of the medical equipment provider’s stock valued at $2,020,000 after buying an additional 60,000 shares during the period. 44.13% of the stock is owned by institutional investors and hedge funds.
SeaSpine Company Profile
SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment.
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.